-+ 0.00%
-+ 0.00%
-+ 0.00%
Sandoz wins Health Canada approval for generic semaglutide injection
Share
Listen to the news
Sandoz wins Health Canada approval for generic semaglutide injection
  • Health Canada granted marketing authorization for Sandoz Semaglutide, a generic version of Novo Nordisk’s Ozempic.
  • Approval covers once-weekly subcutaneous use in adults with type 2 diabetes to improve glycemic control.
  • Product set to launch in three dose strengths via two pen presentations.
  • Sandoz sees no material 2026 financial impact from any potential generic semaglutide launches.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2399568_en) on September 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending